Articles with public access mandates - David M HymanLearn more
Not available anywhere: 6
Review
Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype
MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ...
Clinical Cancer Research 23 (20), 6094-6100, 2017
Mandates: US National Institutes of Health
Review
89Zr-trastuzumab PET/CT for detection of human epidermal growth factor receptor 2–positive metastases in patients with human epidermal growth factor receptor 2–negative primary …
GA Ulaner, DM Hyman, SK Lyashchenko, JS Lewis, JA Carrasquillo
Clinical nuclear medicine 42 (12), 912-917, 2017
Mandates: US Department of Defense, US National Institutes of Health
Review
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome
DM Hyman, L Bakios, G Gualtiere, C Carr, RN Grisham, V Makker, ...
Gynecologic oncology 129 (1), 58-62, 2013
Mandates: US National Institutes of Health
Review
Detection of an NRAS mutation in Erdheim-Chester disease
EL Diamond, O Abdel-Wahab, E Pentsova, L Borsu, A Chiu, ...
Blood, The Journal of the American Society of Hematology 122 (6), 1089-1091, 2013
Mandates: US National Institutes of Health
Review
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
K Jhaveri, MT Chang, D Juric, C Saura, V Gambardella, A Melnyk, ...
Clinical Cancer Research 27 (2), 447-459, 2021
Mandates: US National Institutes of Health
Review
Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control …
ML LeNoue-Newton, SC Chen, T Stricker, DM Hyman, N Blauvelt, ...
Clinical Cancer Research 28 (10), 2118-2130, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Available somewhere: 172
Review
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
Mandates: US National Institutes of Health
Review
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, ...
New England Journal of Medicine 378 (8), 731-739, 2018
Mandates: US National Institutes of Health
Review
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
Mandates: US National Institutes of Health
Review
A view on drug resistance in cancer
N Vasan, J Baselga, DM Hyman
Nature 575 (7782), 299-309, 2019
Mandates: US National Institutes of Health
Review
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
Mandates: US National Institutes of Health
Review
AACR Project GENIE: powering precision medicine through an international consortium
AACR Project Genie Consortium, AACR Project GENIE Consortium, ...
Cancer discovery 7 (8), 818-831, 2017
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, Dutch …
Review
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Review
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
Mandates: US National Institutes of Health
Review
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, ...
The Lancet Oncology 21 (4), 531-540, 2020
Mandates: US National Institutes of Health
Review
Clinical sequencing defines the genomic landscape of metastatic colorectal cancer
R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ...
Cancer cell 33 (1), 125-136. e3, 2018
Mandates: US National Institutes of Health
Review
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ...
Cell stem cell 21 (3), 374-382. e4, 2017
Mandates: US National Science Foundation, US National Institutes of Health, V …
Review
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
Mandates: US National Institutes of Health
Review
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
Mandates: US National Institutes of Health
Review
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
EL Diamond, L Dagna, DM Hyman, G Cavalli, F Janku, J Estrada-Veras, ...
Blood, The Journal of the American Society of Hematology 124 (4), 483-492, 2014
Mandates: US National Institutes of Health, Government of Italy
Publication and funding information is determined automatically by a computer program